Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pfeiffer Syndrome”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03230318
What this trial is testing

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Basilea Pharmaceutica 148
Testing effectiveness (Phase 2)UnknownNCT06022289
What this trial is testing

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Who this might be right for
Solid TumorFGF Receptor Gene MutationFGF Amplification+2 more
Tianjin Medical University Second Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01719549
What this trial is testing

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Who this might be right for
Gastric Cancer
Asan Medical Center 19
Not applicableLooking for participantsNCT06793709
What this trial is testing

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Who this might be right for
Biliary Tract Cancer
Eisai Co., Ltd. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Testing effectiveness (Phase 2)Looking for participantsNCT07359820
What this trial is testing

Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Who this might be right for
FGFR2 Gene Fusion/RearrangementOther Solid Tumors, Adult
Elevar Therapeutics 30
Testing effectiveness (Phase 2)Looking for participantsNCT06728410
What this trial is testing

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce 38
Testing effectiveness (Phase 2)Looking for participantsNCT07292168
What this trial is testing

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Who this might be right for
Renal Cell Carcinoma MetastaticProstate Cancer MetastaticNon-small Cell Lung Cancer Metastatic+2 more
Kidney Cancer Research Bureau 58